{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T20:32:12Z","timestamp":1772397132817,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40123-022-00504-z","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T12:02:53Z","timestamp":1650024173000},"page":"1217-1229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries"],"prefix":"10.1007","volume":"11","author":[{"given":"Sarah","family":"Lebrize","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8818","authenticated-orcid":false,"given":"Louis","family":"Arnould","sequence":"additional","affiliation":[]},{"given":"Abderrahmane","family":"Bourredjem","sequence":"additional","affiliation":[]},{"given":"Catharina","family":"Busch","sequence":"additional","affiliation":[]},{"given":"Matus","family":"Rehak","sequence":"additional","affiliation":[]},{"given":"Pascale","family":"Massin","sequence":"additional","affiliation":[]},{"given":"Joao","family":"Barbosa-Breda","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[]},{"given":"Cesare","family":"Mariotti","sequence":"additional","affiliation":[]},{"given":"Mahmoud","family":"Hamza","sequence":"additional","affiliation":[]},{"given":"Alice","family":"Grise-Dulac","sequence":"additional","affiliation":[]},{"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[]},{"given":"Stephanie","family":"Baillif","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"N Cho","year":"2018","unstructured":"Cho N, Shaw J, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"504_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"4","key":"504_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/09286580701396720","volume":"14","author":"BE Kobrin Klein","year":"2007","unstructured":"Kobrin Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179\u201383.","journal-title":"Ophthalmic Epidemiol"},{"issue":"7","key":"504_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375\u201394.","journal-title":"Ophthalmology"},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","volume":"34","author":"I Klaassen","year":"2013","unstructured":"Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19\u201348.","journal-title":"Prog Retin Eye Res"},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"ETDRSR Group","year":"1985","unstructured":"ETDRSR Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796\u2013806.","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"504_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013\u201322.","journal-title":"Ophthalmology"},{"issue":"1","key":"504_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archopht.121.1.57","volume":"121","author":"JB Jonas","year":"2003","unstructured":"Jonas JB, Kreissig I, S\u00f6fker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121(1):57\u201361.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"504_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","volume":"128","author":"JA Haller","year":"2010","unstructured":"Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289\u201396.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"504_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ophtha.2009.10.040","volume":"117","author":"DRCR Network","year":"2010","unstructured":"DRCR Network. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087-1093.e3.","journal-title":"Ophthalmology"},{"issue":"4","key":"504_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185\u2013222.","journal-title":"Ophthalmologica"},{"issue":"12","key":"504_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1001\/archopht.122.12.1801","volume":"122","author":"HL Brooks","year":"2004","unstructured":"Brooks HL, Caballero S, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122(12):1801\u20137.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"504_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583\u20137.","journal-title":"Ophthalmology"},{"issue":"7","key":"504_CR14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ophtha.2009.11.024","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393-1399.e3.","journal-title":"Ophthalmology"},{"issue":"10","key":"504_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125\u201332.","journal-title":"Ophthalmology"},{"issue":"4","key":"504_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635. e2.","journal-title":"Ophthalmology"},{"issue":"9","key":"504_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/eye.2015.98","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Bailey C, Holz F, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye. 2015;29(9):1173\u201380.","journal-title":"Eye"},{"issue":"12","key":"504_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-021-01542-w","volume":"31","author":"C Bailey","year":"2021","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye. 2021;31(12):1\u20137. https:\/\/doi.org\/10.1038\/s41433-021-01542-w.","journal-title":"Eye"},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2147\/OPTH.S105385","volume":"10","author":"P Massin","year":"2016","unstructured":"Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257\u201364.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"504_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3928\/23258160-20160419-05","volume":"47","author":"RK Parrish","year":"2016","unstructured":"Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):426\u201335.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"sup2","key":"504_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03007995.2017.1366645","volume":"33","author":"SE Holden","year":"2017","unstructured":"Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 \u00b5g intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33(sup2):5\u201317.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"504_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, de Sousa JPC, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103(8):1072\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"9596","key":"504_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"8","key":"504_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1097\/IAE.0b013e3181b32cfd","volume":"29","author":"GL Spaeth","year":"2009","unstructured":"Spaeth GL, de Barros DSM, Fudemberg SJ. Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina. 2009;29(8):1057\u201361.","journal-title":"Retina"},{"issue":"7","key":"504_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352\u20139.","journal-title":"Retina"},{"key":"504_CR26","first-page":"570","volume-title":"Linear mixed models for longitudinal data","author":"G Verbeke","year":"2009","unstructured":"Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. 2nd ed. Springer; 2009. p. 570.","edition":"2"},{"key":"504_CR27","doi-asserted-by":"publisher","DOI":"10.1201\/9781420075779","volume-title":"Logistic regression models","author":"JM Hilbe","year":"2009","unstructured":"Hilbe JM. Logistic regression models. Englewood Cliffs: Chapman & Hall; 2009."},{"issue":"11","key":"504_CR28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780131106","volume":"13","author":"SR Lipsitz","year":"1994","unstructured":"Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med. 1994;13(11):1149\u201363.","journal-title":"Stat Med"},{"issue":"2","key":"504_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","volume":"30","author":"AJ Augustin","year":"2020","unstructured":"Augustin AJ, Bopp S, Fechner M, et al. Three-year results from the Retro-IDEAL study: real-world data from diabetic macular edema (DME) patients treated with ILUVIEN\u00ae (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2020;30(2):382\u201391.","journal-title":"Eur J Ophthalmol"},{"key":"504_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00592-019-01439-x","volume":"57","author":"M Rehak","year":"2019","unstructured":"Rehak M, Busch C, Unterlauft J-D, Jochmann C, Wiedemann P. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Acta Diabetol. 2019;57:469\u201378.","journal-title":"Acta Diabetol"},{"issue":"3","key":"504_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40123-019-0197-3","volume":"8","author":"JF Young","year":"2019","unstructured":"Young JF, Walkden A, Stone A, Mahmood S. Clinical effectiveness of intravitreal fluocinolone acetonide (FAc)(ILUVIEN\u2122) in patients with diabetic macular oedema (DMO) refractory to prior therapy: the Manchester experience. Ophthalmol Ther. 2019;8(3):477\u201384.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"504_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-0726-1","volume":"18","author":"W Fusi-Rubiano","year":"2018","unstructured":"Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19 mg Fluocinolone Acetonide intravitreal implant (Iluvien\u2122) at 2 years. BMC Ophthalmol. 2018;18(1):1\u20137.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"504_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000455235","volume":"57","author":"J Figueira","year":"2017","unstructured":"Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN\u00ae in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166\u201372.","journal-title":"Ophthalmic Res"},{"key":"504_CR34","doi-asserted-by":"crossref","unstructured":"Kodjikian L, Bandello F, De Smet M, Dot C, Zarranz-Ventura J, Loewenstein A, Sudhalkar S, Bilgic A, Cunha-Vaz J, Dirven W, Behar-Cohen F, Mathis T. Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm. Eur J Ophthalmol. 2022 (Online ahead of print).","DOI":"10.1177\/11206721221080288"},{"key":"504_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40123-021-00427-1","volume":"11","author":"FJ Go\u00f1i","year":"2022","unstructured":"Go\u00f1i FJ, Barton K, Dias JA, Diestelhorst M, Garcia-Feijoo J, Hommer A, Kodjikian L, Nicol\u00f2 M. Intravitreal corticosteroid implantation in diabetic macular edema: updated European consensus guidance on monitoring and managing intraocular pressure. Ophthalmol Ther. 2022;11:15\u201334.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"504_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","volume":"8","author":"A Eaton","year":"2019","unstructured":"Eaton A, Koh SS, Jimenez J, Riemann CD. The USER study: a chart review of patients receiving a 0.2 \u00b5g\/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51\u201362.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"504_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","volume":"2","author":"U Pleyer","year":"2013","unstructured":"Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55\u201372.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"504_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ajo.2007.04.021","volume":"144","author":"D Shukla","year":"2007","unstructured":"Shukla D, Vidhya N, Prasad NM, Mahalakshmi R, Kolluru C, Krishnadas R. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144(3):453\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"504_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40123-016-0052-8","volume":"5","author":"FJ Go\u00f1i","year":"2016","unstructured":"Go\u00f1i FJ, Stalmans I, Denis P, et al. Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther. 2016;5(1):47\u201361.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"504_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.eye.6701895","volume":"20","author":"J Kersey","year":"2006","unstructured":"Kersey J, Broadway D. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20(4):407\u201316.","journal-title":"Eye"},{"key":"504_CR41","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41433-020-01373-1","volume":"35","author":"MV Cicinelli","year":"2021","unstructured":"Cicinelli MV, Rosenblatt A, Grosso D, et al. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. Eye. 2021;35:3232\u201342.","journal-title":"Eye"},{"key":"504_CR42","unstructured":"Electronic Medicines Compendium. ILUVIEN 190\u00a0\u00b5g intravitreal implant in applicator. Summary of Product Characteristics; 2019. https:\/\/www.medicines.org.uk\/emc\/medicine\/27636. Accessed June 27, 2021."},{"key":"504_CR43","unstructured":"Food & Drug Administration. ILUVIEN 0.19 mg New Drug Application (NDA 201923); 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/201923s000lbl.pdf. Accessed June 27, 2021."},{"issue":"9","key":"504_CR44","first-page":"1898","volume":"59","author":"M Ulbig","year":"2018","unstructured":"Ulbig M, Wehrmann K, Maier M. Second-line treatment with Iluvien for persistent pre-treated diabetic macular edema. Investig Ophthalmol Vis Sci. 2018;59(9):1898\u20131898.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"504_CR45","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/02713683.2017.1313430","volume":"42","author":"O Ayar","year":"2017","unstructured":"Ayar O, Alpay A, Koban Y, et al. The effect of dexamethasone intravitreal implant on retinal nerve fiber layer in patients diagnosed with branch retinal vein occlusion. Curr Eye Res. 2017;42(9):1287\u201392.","journal-title":"Curr Eye Res"},{"key":"504_CR46","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2147\/OPTH.S252359","volume":"14","author":"A Ad\u00e1n","year":"2020","unstructured":"Ad\u00e1n A, Cabrera F, Figueroa MS, et al. Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien\u00ae) and follow-up considerations\/recommendations. Clin Ophthalmol. 2020;14:2091\u2013107.","journal-title":"Clin Ophthalmol"},{"key":"504_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ogla.2021.04.008","volume":"4","author":"M Schlenker","year":"2021","unstructured":"Schlenker M, Kansal V. How mean intraocular pressures are failing patients. Ophthalmol Glaucoma. 2021;4:553\u20137.","journal-title":"Ophthalmol Glaucoma"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00504-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:07:29Z","timestamp":1652814449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00504-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00504-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}